Objective: To systemically evaluate the efficacy and the safety of modified Shashen Maidong Tang combined with chemotherapy in treating patients with non-small cell lung cancer. Method: We searched randomized controlled clinical studies on modified Shashen Maidong Tang combined with chemotherapy for non-small cell lung cancer in the databases of CNKI

Wanfang Data

VIP

CBM and PubMed from the database building date to 2015.Articles were selected in accordance with the inclusion/exclusion criteria;quality of included studies was evaluated and data was extracted

then Revmen5.3 software was used for Meta-analysis. Result: The 10 randomized controlled trials were included for systematic review

all of which were of low quality studies with Jadad score<3.Meta results showed that:compared with the control group

the effective rate [OR= 1.70

95%CI (1.25

2.31)

P=0.000 7] and stable rate [OR=2.26

95%CI (1.51

3.37)

P<0.000 1] of Shashen Maidong Tang combined with chemotherapy for non-small cell lung were higher

and it could reduce bone marrow suppression [OR=0.42

95%CI (0.23

0.78)

P=0.006]

with statistically significant difference. In respect of reducing liver function [OR=0.67

95%CI (0.38

1.20)

P=0.18]

renal impairment [OR=0.77

95%CI (0.38

1.57)

P=0.48] and gastrointestinal symptoms [OR=0.61

95%CI (0.34

1.12)

P=0.11]

there was no significant difference between Shashen Maidong Tang combined with chemotherapy group and control group. Conclusion: Shashen Maidong Tang combined with chemotherapy for non-small cell lung cancer have better efficacy and could reduce side effects of chemotherapy such as marrow suppression. However

the existing research evidence level is low

and more large-sample

high-quality

and multi-center randomized controlled trials are still needed for further verification.